# EDGAR Filing Document

**Accession Number:** 0001347178
**File Stem:** 0000000000-26-001642
**Filing Date:** 2026-2
**Character Count:** 2248
**Document Hash:** c41ec3d485a3ed76ace91f34d21b2f50
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-001642.hdr.sgml**: 20260603

**ACCESSION NUMBER**: 0000000000-26-001642

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260218

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vanda Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001347178
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 030491827
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-293404

**BUSINESS ADDRESS:**
- **STREET 1:** 2200 PENNSYLVANIA AVE NW
- **STREET 2:** SUITE 300E
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20037
- **BUSINESS PHONE:** 202-734-3400

**MAIL ADDRESS:**
- **STREET 1:** 2200 PENNSYLVANIA AVE NW
- **STREET 2:** SUITE 300E
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20037
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001628280-26-007476

## Text-Extract

```

                                                           February 18, 2026

Mihael Polymeropoulos
Chief Executive Officer
Vanda Pharmaceuticals Inc.
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037

       Re: Vanda Pharmaceuticals Inc.
           Registration Statement on Form S-3
           Filed February 12, 2026
           File No. 333-293404
Dear Mihael Polymeropoulos:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Tyler Howes at 202-551-3370 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Gregg A. Griner, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._